Reports from the Study AP32788-15-101 led to FDA approval of mobocertinib for locally advanced or metastatic NSCLC with EGFR exon 20 insertion on September 15, 2021 [33]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.